Stay updated on Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page.

Latest updates to the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now displays the ClinicalTrials.gov record for a phase 2 study of pembrolizumab and pelareorep for advanced pancreatic cancer. It includes the study’s terminated status, results, eligibility criteria, treatment plan, outcome measures, and a link to its protocol and statistical analysis plan.SummaryDifference56%

- Check17 days agoChange DetectedThe footer's site revision label changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA notice was added announcing NIH’s transition from the term “Artificial Intelligence” to “Super Intelligence” and linking to updates and FAQs.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision label changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 Forbidden page; the study record remains inaccessible.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision changed from v3.7.0 to v3.7.1; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe page now displays a 403 Forbidden screen instead of the study details, indicating the study record cannot be accessed at this time.SummaryDifference20%

Stay in the know with updates to Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab and Pelareorep in Advanced Pancreatic Cancer Clinical Trial page.